This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Thoughts, Appraisals, Lingering Questions From Celgene's $7 Receptos Buy

Receptos' ozanimod is one of the most compelling late-stage assets in biotech, which makes Celgene's decision to buy it look smart.

Gilead Hep C Sales Under Investor Microscope as Earnings Near

The total number of prescriptions written for Gilead Sciences hepatitis C drugs Sovaldi and Harvoni in the U.S. peaked in March and are now in a consistent downtrend.

Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test

Anacor intends to seek U.S. approval for a skin rash lotion, crisaborole, in the first half of next year, based on data collected from studies.

Northwest Bio Shareholders May Have Been Undercut by CEO

The loans negotiated by CEO Linda Powers to a private firm she controls doesn't appear to violate securities laws, but she may have breached fiduciary duty to Northwest Bio shareholders.

Previewing the Next Look at Biogen's Alzheimer's Drug

On Saturday, July 18, Biogen will present updated results from a closely watched clinical trial involving its Alzheimer's drug candidate aducanumab (formerly known as BIIB037).

Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock

Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.

Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Page 3 of 340
Top Rated Stocks Top Rated Funds Top Rated ETFs